Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Nektar Therapeutics
NKTR | US
91.68
USD0.42
0.46%
NKTR | US
Loading StockChartView...
About Nektar Therapeutics
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
91.68
Open
91.88
High
92.06
Low
88.69
Nektar Therapeutics a biopharmaceutical company focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255 an IL-15 receptor agonist which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals Inc. The company was incorporated in 1990 and is headquartered in San Francisco California.
View LessNKTR | US
Risk
82.4
Sharpe
4.18
Luna's Score
63/100
Recommendation
Hold
Luna says (NKTR | US)
What's Working
Positive Momentum
Largecap (10B - 200B USD)
Low Market Beta (-0.4 to 0.8)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
What's not Working
High 6-Month Volatility (>65%)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
95.5%1 month
82.4%3 months
124.1%6 months
104.3%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.26
Debt to equity
2.76
Debt to assets
0.64
Ent. to EBITDA
-6.50
Ent. to rev.
1.08
PEG
3.22
Other Fundamentals
EBITDA
-128.69M
MarketCap
16.88B
MarketCap(USD)
16.88B
Div. yield
-
Op. margin
-155.33
Erngs. growth
-
Rev. growth
14.60
Ret. on equity
-128.02
Short ratio
8.50
Short perc.
5.08
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
32.49
Range1M
44.90
Range3M
75.60
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.79
Price X volume
84.46M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -6.50 | 0.53 | Cheaper |
| Ent. to Revenue | 1.08 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.26 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 124.09 | 72.80 | Riskier |
| Debt to Equity | 2.76 | -1.23 | Expensive |
| Debt to Assets | 0.64 | 0.25 | Expensive |
| Market Cap | 16.88B | 3.66B | Market Leader |
